Yale Cancer Center researchers have made a significant advance in understanding the mechanisms of resistance to targeted therapies used in the treatment of lung adenocarcinoma driven by EGFR mutations.
- August 31, 2022
Study from Yale Cancer Biologists Identifies Chromatin Regulator WDR5 as Possible Drug Target in Triple-Negative Breast Cancer
A new study from Yale Cancer Center scientists has identified the chromatin regulator WDR5 as a possible new drug target in triple negative breast cancer.
- April 11, 2022
American Society for Investigative Pathology to Honor Qin Yan, PhD, with 2023 Outstanding Investigator Award
The American Society for Investigative Pathology has announced it will honor Qin Yan, PhD, Associate Professor of Pathology at Yale School of Medicine, with its 2023 Outstanding Investigator Award.
- March 02, 2022Source: Yale Daily News
Yale researchers found that the epigenetic regulator gene cat eye syndrome chromosome region candidate 2, or CECR2, is responsible for driving breast cancer metastasis –– making it exponentially more difficult to treat.
- February 21, 2022
Three Yale Pathology faculty members were recently honored for their contributions to cancer research and education during the Yale Cancer Center Annual Conclave on February 15, 2022.
- February 01, 2022
A new study by researchers at Yale Cancer Center shows inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing.
- October 20, 2021
A new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity.
- February 24, 2021
When lung cancer and breast cancer relapse, they often metastasize in the brain. The tumors that arise in the brain develop novel characteristics, differences that oft en confer resistance to existing drug therapies and create opportunities for new detection and treatment approaches for Yale Cancer Center researchers.
- April 15, 2020
A class of experimental cancer drugs called BET inhibitors have shown promise for treating cancers of the blood, but can induce toxic side effects. Now Yale researchers have found a new inhibitor that in animal studies demonstrates greater potency against a wider variety of cancers, as well as against solid tumors, and also produces fewer side effects compared to others in the class.
- January 29, 2020
Qin Yan, Ph.D., was presented with the Yale Cancer Center (YCC) Class of 1961 Cancer Research Award at YCC’s annual Conclave.